Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation

Therapeutic Drug Monitoring

Volumn 36, Issue 1, 2014, Pages 46-53

  Sæves, Ingjerd ^a,b   Line, Pål Dag ^c   Bremer, Sara ^a   Vethe, Nils T ^a   Tveit, Ragnhild G ^a   Meltevik, Tore J ^a   Bergan, Stein ^b,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Department of Transplantation Medicine ^*  (United States)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

IMPDH; inosine monophosphate dehydrogenase; liver transplantation; mycophenolic acid; tacrolimus; therapeutic drug monitoring

Indexed keywords

INOSINATE DEHYDROGENASE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; ELECTROSPRAY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIQUID CHROMATOGRAPHY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; YOUNG ADULT;

ADULT; AGED; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TACROLIMUS; TIME FACTORS; YOUNG ADULT;

EID: 84892902706     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31829dcb66     Document Type: Article

References (34)

1. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85-118.
2. Natsumeda Y, Ohno S, Kawasaki H, et al. Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem. 1990;265:5292-5295.
3. Carr SF, Papp E, Wu JC, et al. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem. 1993;268:27286-27290.
4. Sombogaard F, van Schaik RH, Mathot RA, et al. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T.C polymorphism. Pharmacogenet Genomics. 2009;19:626-634.
5. Winnicki W, Weigel G, Sunder-Plassmann G, et al. An inosine 5'-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid. Pharmacogenomics J. 2010;10:70-76.
6. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46:13-58.
7. Bowalgaha K, Miners JO. The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol. 2001;52:605-609.
8. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
9. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005;5:987-994.
10. Kobayashi M, Saitoh H, Kobayashi M, et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther. 2004;309:1029-1035.
11. Bernard O, Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos. 2004;32:775-778.
12. Kuypers DR, Naesens M, Vermeire S, et al. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther. 2005;78:351-361.
13. van Schaik RH, van Agteren M, de Fijter JW, et al. UGT1A9-275T.A/-2152C.T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther. 2009;86:319-327.
14. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995; 17:584-591.
15. Sattler M, Guengerich FP, Yun CH, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992;20:753-761.
16. Wacher VJ, Silverman JA, Zhang Y, et al. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci. 1998;87:1322-1330.
17. de Jonge H, de Loor H, Verbeke K, et al. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther. 2012;92: 366-375.
18. Lo A, Burckart GJ. P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol. 1999;39:995-1005.
19. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001;23:305-315.
20. Svensson JO, Brattstrom C, Sawe J. A simple HPLC method for simultaneous determination of mycophenolic acid and mycophenolic acid glucuronide in plasma. Ther Drug Monit. 1999;21:322-324.
21. Vethe NT, Bergan S. Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy. Ther Drug Monit. 2006;28:608-613.
22. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther. 1995;57: 281-290.
23. Bauer AJ, Boeckxstaens GE. Mechanisms of postoperative ileus. Neurogastroenterol Motil. 2004;16(suppl 2):54-60.
24. Wallden J, Thorn SE, Lovqvist A, et al. The effect of anesthetic technique on early postoperative gastric emptying: comparison of propofolremifentanil and opioid-free sevoflurane anesthesia. J Anesth. 2006;20: 261-267.
25. Pascussi JM, Gerbal-Chaloin S, Drocourt L, et al. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta. 2003;1619:243-253.
26. Hesselink DA, Ngyuen H, Wabbijn M, et al. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br J Clin Pharmacol. 2003;56: 327-330.
27. van Duijnhoven EM, Boots JMM, Christiaans MHL, et al. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int. 2003;16: 721-725.
28. Lodewijk L, Mall A, Spearman CW, et al. Effect of liver regeneration on the pharmacokinetics of immunosuppressive drugs. Transplant Proc. 2009;41:379-381.
29. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997;62:248-260.
30. Jain A, Venkataramanan R, Hamad IS, et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol. 2001;41:268-276.
31. Jain A, Venkataramanan R, Kwong T, et al. Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. Liver Transpl. 2007;13:791-796.
32. Girard H, Court MH, Bernard O, et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics. 2004;14:501-515.
33. Bremer S, Mandla R, Vethe NT, et al. Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression. Transplantation. 2008;85:55-61.
34. Bremer S, Vethe NT, Rootwelt H, et al. Expression of IMPDH1 is regulated in response to mycophenolate concentration. Int Immunopharmacol. 2009;9:173-180.